
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a veterinarian's order for one animal patient. Not FDA-approved.
Itraconazole is an FDA-approved animal drug. Itrafungol (itraconazole oral solution, NADA 141-474) is labeled for oral use in cats only and is indicated for the treatment of dermatophytosis (ringworm) caused by Microsporum canis in cats. Animal Drugs@FDA lists no other approved animal itraconazole product. The label notes the solution is given by mouth with an enclosed dosing syringe. Itraconazole is also used in human medicine. Compounded preparations are not FDA-approved and are dispensed only on a veterinarian's prescription for an individual animal.
The Itrafungol label says not to give it to cats allergic to itraconazole, and that it has not been shown to be safe in pregnant cats. Side effects reported after approval include poor appetite, vomiting, raised liver enzymes, tiredness, weight loss, yellowing of the skin or eyes, and diarrhea; some deaths have been reported. Ringworm can spread to people, so wear gloves when handling a treated cat and see a doctor about any suspicious skin spot. Merck notes African grey parrots appear more sensitive to itraconazole. Azole antifungals slow the breakdown of many other drugs. Ask your veterinarian or pharmacist about other medicines and supplements your animal takes.
Compounding from approved Itrafungol is extralabel use permitted under 21 CFR 530.13(b) only when no approved animal or human drug, used as labeled or in conformity with the extralabel criteria of part 530, will, in the available dosage form and concentration, appropriately treat the condition diagnosed; 530.13(a) excludes compounding from bulk. GFI #256 office stock covers itraconazole only with DMSO, ophthalmic, for horses (updated 10/05/2026). Merck states oral bioavailability can be very poor with noncommercial azoles, advises caution with compounded products and notes a human boxed warning for negative inotropy. A February 21, 2023, FDA CVM safety-related labeling change for Itrafungol added liver-related precautions and post-approval adverse events, including deaths.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally